Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Trading 11-26 10:55:56 EST

55.92

-0.73

-1.30%

High56.77	Low55.71	Vol186.20M
Open56.71	D1 Closing56.65	Amplitude1.87%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O4.41B	T/O Rate--	Tradable Shares0.00
P/B5.584255	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":55.919502,"timestamp":1732636555860,"preClose":56.65334,"halted":0,"volume":186198022,"delay":0,"changeRate":-0.012953,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.733837,"latestTime":"11-26 10:55:56 EST","open":56.710743,"high":56.773037,"low":55.714096,"amount":4410722032.862202,"amplitude":0.018692,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732654800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.584255,"peRate":-52.36142,"turnoverRate":0.005894,"increases":266,"decrements":299,"flats":17,"marketCap":1470751851412.25,"floatMarketCap":1316851901410.4375},"requestUrl":"/m/hq/s/BK4139/wiki","defaultTab":"wiki","newsList":[{"id":"2486046848","title":"Poseida Therapeutics Surges 224% As Roche to Acquire the US Firm in $1.5 Bln Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486046848","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486046848?lang=en_us&edition=fundamental","pubTime":"2024-11-26 22:56","pubTimestamp":1732632965,"startTime":"0","endTime":"0","summary":" - Switzerland's Roche will acquire U.S. biopharma firm Poseida Therapeutics in a cash deal worth up to $1.5 billion, the companies said on Tuesday.Poseida Therapeutics shares jumped 224% in morning trading.Poseida is to be bought at $9 per share in cash, and stockholders will also receive a non-tradeable contingent value right for up to $4 per share if specific milestones are met, taking the deal value to up to around $1.5 billion.It is expected to close in the first quarter of 2025.\"We have wo","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche to Acquire US Firm Poseida Therapeutics in $1.5 Bln Deal","news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSTX","BK4139"],"gpt_icon":0},{"id":"2486025210","title":"Poseida Therapeutics Shares up 216.8% Premarket After Roche to Acquire Co in $1.5 Bln Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2486025210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486025210?lang=en_us&edition=fundamental","pubTime":"2024-11-26 17:06","pubTimestamp":1732611995,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3N3MX0OO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSTX"],"gpt_icon":0},{"id":"2486026597","title":"Moderna: Optimistic Outlook Despite The Recent Sell-Off","url":"https://stock-news.laohu8.com/highlight/detail?id=2486026597","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486026597?lang=en_us&edition=fundamental","pubTime":"2024-11-26 16:51","pubTimestamp":1732611087,"startTime":"0","endTime":"0","summary":"Moderna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year.3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV vaccine sales underperformed.The pipeline includes promising next-gen COVID-19, RSV, flu, CMV, norovirus, and oncology drugs, with substantial revenue potential by 2027.Short positions, tax-loss selling, and political risks may pressure shares near-term, but long-term growth prospects remain strong.   hapabapa  Background As part of my previous article, I noted the undervaluation of Moderna's  stock. But since then, the stock has lost 37% of its value. Several factors have contributed to this loss. In this article, I will provide a more detailed","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417795138/image_1417795138.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417795138/image_1417795138.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4740279-moderna-optimistic-outlook-despite-the-recent-sell-off","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4548","BK4139","BK4551","BK4533","BK4501","BK4588","MRNA","BK4585","BK4568","BK4534","BK4532"],"gpt_icon":1},{"id":"2486602359","title":"Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2486602359","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486602359?lang=en_us&edition=fundamental","pubTime":"2024-11-26 16:40","pubTimestamp":1732610400,"startTime":"0","endTime":"0","summary":"Roche agreed to buy San Diego-based Poseida Therapeutics in a deal worth up to $1.5 billion, as the company seeks to expand its pipeline and support growth.The deal allows the Swiss pharmaceutical company to bring in house its current partner with the aim of developing cell therapies in oncology, immunology and neurology. The move is part of Roche's efforts to replenish its drug pipeline and drive sales growth toward the end of the decade.Roche said Tuesday that it entered into a definitive merger agreement to acquire Poseida Therapeutics for about $1 billion, or $9 a share, with additional performance-related payments worth up to $4.00 a share that could take the full deal value to around $1.5 billion. Poseida shares closed at $2.86 on Monday.The two companies have been working together since 2022 to develop CAR-T cell therapies for patients with hematological malignancies.CAR-T cell therapies are customized for individual patients and are made by collecting a patient's own T cells, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","RHHBY","PSTX","03165"],"gpt_icon":1},{"id":"2486566047","title":"I-Nexus Global Plans AIM Delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2486566047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486566047?lang=en_us&edition=fundamental","pubTime":"2024-11-26 15:55","pubTimestamp":1732607700,"startTime":"0","endTime":"0","summary":"I-Nexus Global is seeking shareholder approval to cancel its trading on London's junior AIM, citing a weak share price performance and low liquidity.The cloud-based software solutions company said Tuesday that re-registering as a private company will allow it to focus on achieving profitability, enhancing stability and enable it to deliver on the board's growth strategy.A general shareholder meeting will be held on Dec. 13, and if the plan is approved the company expects trading in its shares to be cancelled from Dec. 27.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIM","BK4557","BK4139"],"gpt_icon":0},{"id":"2486837042","title":"Best Buy, HP And 3 Stocks To Watch Heading Into Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2486837042","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486837042?lang=en_us&edition=fundamental","pubTime":"2024-11-26 15:42","pubTimestamp":1732606936,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/42181574/best-buy-hp-and-3-stocks-to-watch-heading-into-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4076","BK4139","BK4551","LU0942090050.USD","BK4505","HPQ","BK4548","LU1861558580.USD","BK4535","LU0072461881.USD","BK4533","LU0162691827.USD","BK4567","DELL","BK4588","LU0868494617.USD","LU1861559042.SGD","BK4525","LU0868494708.USD","BK4515","BK4585","BK4528","BK4092","LU0267386448.USD","BK4532","BBY","LU0006061336.USD","HP","BK4554","ZM","BK4170","PSTX"],"gpt_icon":1},{"id":"2486044276","title":"LIVE MARKETS-Europe before the bell: Trump tariff jitters weigh","url":"https://stock-news.laohu8.com/highlight/detail?id=2486044276","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486044276?lang=en_us&edition=fundamental","pubTime":"2024-11-26 15:38","pubTimestamp":1732606684,"startTime":"0","endTime":"0","summary":"LIVE MARKETS-Europe before the bell: Trump tariff jitters weigh Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at market","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL5N3MX0C0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1078025761.USD","LU0345777659.USD","LU0106831901.USD","LU1064927863.SGD","PSTX","BK4139","BK5152","LU0048578792.EUR","LU0997586606.USD","LU0047473722.EUR","LU0161305163.EUR","LU0345777147.USD","LU0964806797.USD","BARC.UK","LU1791807156.HKD","LU0550127509.SGD","LU0047473722.SGD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2486017044","title":"BerGenBio Highlights Clinical Progress and Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486017044","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486017044?lang=en_us&edition=fundamental","pubTime":"2024-11-26 15:34","pubTimestamp":1732606446,"startTime":"0","endTime":"0","summary":"BerGenBio ASA (BRRGF) has released an update. BerGenBio ASA has announced that CEO Olav Hellebø will present a business update at the DNB Nordic He...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bergenbio-highlights-clinical-progress-and-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bergenbio-highlights-clinical-progress-and-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRRGF","BK4139","PRGS","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2486041677","title":"i-nexus Global to Delist from AIM, Go Private","url":"https://stock-news.laohu8.com/highlight/detail?id=2486041677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486041677?lang=en_us&edition=fundamental","pubTime":"2024-11-26 15:15","pubTimestamp":1732605338,"startTime":"0","endTime":"0","summary":"i-nexus Global plc (GB:INX) has released an update. i-nexus Global plc plans to delist from AIM and re-register as a private company, aiming to boo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/i-nexus-global-to-delist-from-aim-go-private?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/i-nexus-global-to-delist-from-aim-go-private?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AIM","BK4139","BK4557"],"gpt_icon":0},{"id":"2486049918","title":"Bright Minds Biosciences Inc : Baird Initiates Coverage With Outperform Rating and $75 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2486049918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486049918?lang=en_us&edition=fundamental","pubTime":"2024-11-26 15:06","pubTimestamp":1732604811,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MW12D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2486049846","title":"Press Release: Cadeler Reports Strong Q3 Results Backed by Solid Client Demand and High Utilisation of Its Growing, Modern and Flexible Fleet","url":"https://stock-news.laohu8.com/highlight/detail?id=2486049846","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486049846?lang=en_us&edition=fundamental","pubTime":"2024-11-26 15:00","pubTimestamp":1732604400,"startTime":"0","endTime":"0","summary":"Cadeler Reports Strong Q3 Results Backed by Solid Client Demand and High Utilisation of Its Growing, Modern and Flexible Fleet. Today, Cadeler A/S  has published its Q3 Earnings Release, delivering in line with expectations and reporting a backlog approaching EUR 2.4 billion, underscoring consistently strong market demand. In Q3, Cadeler welcomed the Wind Peak, the latest addition to its fleet, purpose-built to meet the evolving complexities of future wind farms. Delivered on time and within budget, Wind Peak was promptly deployed for its first project in Europe, demonstrating its readiness to meet the growing demand for flexibility from clients.\"Q3 also marked a milestone with the delivery of Wind Peak, a cutting-edge vessel completed on time and within budget. Her early arrival in Europe allowed us to deploy her on a short-term contract before she commences work","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FID","BK4139","APM"],"gpt_icon":0},{"id":"2486045188","title":"Mount Gibson Iron’s Strategic Buy-Back Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2486045188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486045188?lang=en_us&edition=fundamental","pubTime":"2024-11-26 14:30","pubTimestamp":1732602611,"startTime":"0","endTime":"0","summary":"Mount Gibson Iron Limited (AU:MGX) has released an update. Mount Gibson Iron Limited has updated its ongoing buy-back program, revealing that they ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mount-gibson-irons-strategic-buy-back-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mount-gibson-irons-strategic-buy-back-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MGX"],"gpt_icon":0},{"id":"2486439250","title":"Roche to acquire US-based Poseida Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2486439250","media":"Reuters","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486439250?lang=en_us&edition=fundamental","pubTime":"2024-11-26 14:21","pubTimestamp":1732602115,"startTime":"0","endTime":"0","summary":"Roche to acquire US-based Poseida Therapeutics BERLIN, Nov 26 (Reuters) - Roche ROG.S will acquire California-based biopharmafirm Poseida Therapeutics PSTX.O for $9 per share at closing, for a total e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nTUA9JLZGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSTX"],"gpt_icon":0},{"id":"2486487130","title":"Poseida Therapeutics, Inc. Announces Agreement to Be Acquired by Roche Holdings, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486487130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486487130?lang=en_us&edition=fundamental","pubTime":"2024-11-26 14:10","pubTimestamp":1732601402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nTUA540JHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSTX","BK4139"],"gpt_icon":0},{"id":"2486043218","title":"Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486043218","media":"PR Newswire","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486043218?lang=en_us&edition=fundamental","pubTime":"2024-11-26 14:10","pubTimestamp":1732601400,"startTime":"0","endTime":"0","summary":"Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right  to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion. Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division. \"Poseida has demonstrated the unique ability of its proprietary non-viral technology platform to create allogeneic, TSCM-rich CAR-T therapies with the potential to improve clinical outcomes and expand access to this important class of medicines. Most recently, this was highlighted by the compelling interim clinical data for P-BCMA-ALLO1 in patients with multiple myeloma,\" saidKristin Yarema, Ph.D., President and Chief Executive Officer ofPoseida Therapeutics. \"We have worked closely with Roche through our collaboration focused on hematologi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/poseida-therapeutics-inc-announces-agreement-061000051.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poseida-therapeutics-inc-announces-agreement-061000051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSTX","CAR","BK4139","BK4161","CVR","BK4230","BK4022"],"gpt_icon":0},{"id":"2486404841","title":"Cibus Inc : Jefferies Cuts Target Price to $5 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2486404841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486404841?lang=en_us&edition=fundamental","pubTime":"2024-11-26 14:06","pubTimestamp":1732601206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MW17I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CBUS"],"gpt_icon":0},{"id":"2486435290","title":"PYC Therapeutics Limited (PYC) Gets a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2486435290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486435290?lang=en_us&edition=fundamental","pubTime":"2024-11-26 14:05","pubTimestamp":1732601129,"startTime":"0","endTime":"0","summary":"In a report released on November 22, Elyse Shapiro from Canaccord Genuity maintained a Buy rating on PYC Therapeutics Limited (PYC – Research Repor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/pyc-therapeutics-limited-pyc-gets-a-buy-from-canaccord-genuity-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/pyc-therapeutics-limited-pyc-gets-a-buy-from-canaccord-genuity-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139"],"gpt_icon":0},{"id":"2486431850","title":"Three Stocks That May Be Trading Below Their Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2486431850","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486431850?lang=en_us&edition=fundamental","pubTime":"2024-11-26 14:02","pubTimestamp":1732600928,"startTime":"0","endTime":"0","summary":"In recent weeks, global markets have experienced a mix of optimism and caution, with U.S. indexes nearing record highs amid strong labor market data and positive sentiment in the housing sector. Meanwhile, geopolitical tensions and economic uncertainties in regions like Europe and Japan have kept investors vigilant as they navigate these complex conditions. In this environment, identifying stocks that may be trading below their estimated value can present unique opportunities for investors seeking to capitalize on potential growth while managing risk effectively.Planisware SAS is trading at 23.95, approximately 19.6% below its estimated fair value of 29.8, suggesting potential undervaluation based on cash flows. Despite a decrease in net income to 15.98 million for the half-year ending June 30, 2024, compared to the previous year, revenue increased to 86.63 million from 72.2 million. Revenue growth is forecasted at 15% annually, surpassing the French market's average growth rate of 5.6","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3wFOxca.gMo3EgB9BjBM9g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/41bdd0c670f621394929d5266c5d6c72","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3wFOxca.gMo3EgB9BjBM9g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/41bdd0c670f621394929d5266c5d6c72"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/three-stocks-may-trading-below-060208671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EQBK","BOEUF","BK4211","5E2.SI","BK4139"],"gpt_icon":0},{"id":"2486401702","title":"Apogee Therapeutics Inc : Canaccord Genuity Initiates Coverage With Buy Rating; Target Price $89","url":"https://stock-news.laohu8.com/highlight/detail?id=2486401702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486401702?lang=en_us&edition=fundamental","pubTime":"2024-11-26 13:39","pubTimestamp":1732599546,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nFWN3MW0X7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","BK4139"],"gpt_icon":0},{"id":"2486010090","title":"Replimune prices $140M offering at $13 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2486010090","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486010090?lang=en_us&edition=fundamental","pubTime":"2024-11-26 13:25","pubTimestamp":1732598734,"startTime":"0","endTime":"0","summary":"Clinical stage biotechnology company Replimune Group  priced its public offering of ~6.92M shares at a public offering price of $13.00 per share.Gross proceeds are expected to be approximately $140M.Underwriters have a 30-day option to purchase up to an additional ~1.62M shares.The offering is expected to close on November 27, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4333597-replimune-prices-140m-offering-at-13-per-share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","REPL"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction